Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJardine Math.sr Regulatory News (JAR)

Share Price Information for Jardine Math.sr (JAR)

Share Price is delayed by 15 minutes
Get Live Data
62.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: $18.42b
JAR Live PriceLast checked at - London Stock Exchange

Intraday Jardine Math.sr Share Chart

Interim Management Statement

18 May 2023 10:23

RNS Number : 8917Z
Mandarin Oriental International Ltd
18 May 2023
 

Announcement

 

The following announcement was issued today to a Regulatory Information Service approved by the Financial Conduct Authority in the United Kingdom.

 

MANDARIN ORIENTAL INTERNATIONAL LIMITED

Interim Management Statement

 

18th May 2023 - Mandarin Oriental International Limited today issues its Interim Management Statement for the first quarter of 2023.

 

The Group recorded an underlying profit in the first quarter of 2023, driven by improved performance from both the Group's owned hotels and its management business. RevPAR grew substantially in Asia compared to last year, as the region benefitted from the removal of travel restrictions. As a result, the Group's owned hotels saw a significantly improved performance, particularly in Hong Kong, Tokyo, and Bangkok. In the rest of the world, our hotels were also able to achieve a higher RevPAR compared to both last year and 2019, driven by strong rates.

 

The first quarter saw progress on a number of hotel developments. In January, the Group announced a new management contract for a luxury beach resort in Mallorca, Spain, scheduled to open by the end of 2024. In February, after three years' work, the Emirates Palace hotel in Abu Dhabi was rebranded as Emirates Palace Mandarin Oriental, Abu Dhabi. In March, Mandarin Oriental, Singapore, closed for a substantial renovation; it is expected to reopen in September 2023.

 

As a result of improved trading conditions, the Group generated underlying earnings before interest, tax, depreciation, and amortisation ('EBITDA') of US$30 million, a substantial increase from the EBITDA loss of US$1 million in the first quarter of 2022. Owned hotels reported an EBITDA of US$19 million, with almost all hotels delivering increased financial performance. The management business saw significant growth and generated higher fees, with hotels, particularly in Hong Kong and Mainland China, contributing to an EBITDA of US$7 million. Unaudited underlying profit in the first quarter was US$3 million, much improved from an underlying loss of US$26 million in 2022.

 

The Group's redevelopment project in Causeway Bay, Hong Kong, formerly the site of The Excelsior hotel, is ongoing, in line with our budget, and is expected to complete in early 2025.

 

Consolidated net debt as at 31st March 2023 reduced to US$311 million (US$376 million at 31st December 2022). The Group's liquidity position remains robust, with US$453 million in available committed debt facilities and US$306 million of cash reserves. Gearing was 6% of adjusted shareholders' funds.

 

On 2nd May 2023, the Company announced that Laurent Kleitman would replace James Riley as Group Chief Executive of Mandarin Oriental International Limited with effect from 1st September 2023.

 

Mandarin Oriental International Limited is incorporated in Bermuda and has a primary listing in the standard segment of the London Stock Exchange, with secondary listings in Bermuda and Singapore. Mandarin Oriental is a member of the Jardine Matheson Group.

 

- end -

 

For further information, please contact:

 

Mandarin Oriental Hotel Group International Limited

James Riley

(852) 2895 9288

Matthew Bishop

(852) 2895 9288

 

Brunswick Group Limited

William Brocklehurst

(852) 5685 9881

 

This and other Group announcements can be accessed online at 'www.mandarinoriental.com'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCKVLBFXELLBBB
Date   Source Headline
8th May 201912:32 pmRNSInterim Management Statement
2nd May 201910:20 amRNSDividend
29th Apr 201910:49 amRNSFirst Quarter 2019 Results of PT Hero
26th Apr 201910:35 amRNSJC&C 2019 First Quarter Financial Statements
24th Apr 201911:09 amRNSPT Astra 2019 First Quarter Financial Statements
18th Apr 201910:57 amRNSDividend
4th Apr 201910:11 amRNSAnnual Financial Report
29th Mar 20199:15 amRNSTotal Voting Rights
27th Mar 20199:12 amRNSCirc re. Scrip Dividend Scheme
26th Mar 20199:14 amRNSDirector/PDMR Shareholding
25th Mar 20199:12 amRNSBlock listing Interim Review
20th Mar 201910:53 amRNSDirector/PDMR Shareholding
7th Mar 20199:12 amRNSDirector/PDMR Shareholding
28th Feb 20199:25 amRNS2018 Preliminary Announcement of Results
28th Feb 20199:23 amRNS2018 Preliminary Announcement of Results
28th Feb 20199:19 amRNSFull Year 2018 Results of PT Hero
28th Feb 20199:18 amRNS2018 PRELIMINARY ANNOUNCEMENT OF RESULTS
28th Feb 20199:06 amRNS2018 PRELIMINARY ANNOUNCEMENT OF RESULTS
28th Feb 20199:06 amRNS2018 Preliminary Announcement of Results
27th Feb 20199:50 amRNSJC&C 2018 Financial Statements
27th Feb 20199:41 amRNSPT Astra Intl TBK - 2018 FY Financial Statements
31st Jan 20199:07 amRNSTotal Voting Rights
30th Jan 20199:15 amRNSNotice of 2018 Final Results
24th Jan 201911:08 amRNSDirector/PDMR Shareholding
8th Jan 201910:18 amRNSDirector/PDMR Shareholding
31st Dec 20187:00 amRNSTotal Voting Rights
20th Dec 201811:32 amRNSDirector Declaration
17th Dec 20187:00 amRNSDF Increases Interest in Rose Pharmacy Inc to 100%
7th Dec 20189:08 amRNSDirectorate Change
30th Nov 20189:16 amRNSTotal Voting Rights
23rd Nov 20189:10 amRNSDF Completes Partnership with Robinsons in Phl
8th Nov 20189:20 amRNSInterim Management Statement
8th Nov 20189:17 amRNSInterim Management Statement
8th Nov 20189:12 amRNSInterim Management Statement
8th Nov 20189:12 amRNSInterim Management Statement
8th Nov 20189:10 amRNSInterim Management Statement
7th Nov 20189:21 amRNS2018 Third Quarter Financial Statements
31st Oct 20189:10 amRNSTotal Voting Rights
30th Oct 201810:02 amRNSNine Months 2018 Results of PT Hero
29th Oct 20187:00 amRNSPT Astra 2018 Third Quarter Financial Statements
24th Oct 201811:31 amRNSDirector/PDMR Shareholding
11th Oct 201811:52 amRNSDirector/PDMR Shareholding
10th Oct 201810:13 amRNSDirector/PDMR Shareholding
5th Oct 201810:35 amRNSAdditional Listing
2nd Oct 201811:04 amRNSForm 8.3 - Jardine Lloyd Thompson Group plc
2nd Oct 20187:00 amRNSDF Increases Interest in Rose Pharmacy Inc to 100%
1st Oct 20187:00 amRNSDirectorate Change
1st Oct 20187:00 amRNSDirectorate Change
1st Oct 20187:00 amRNSDirectorate Change
1st Oct 20187:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.